US equities
|
NVDA
$238.60
▲+1.99%
SPCX
$167.42
▲+5.32%
MU
$1,062.81
▼-1.12%
TSLA
$380.21
▲+2.60%
MSFT
$525.79
▲+1.60%
SNDK
$1,705.07
▼-0.87%
INTC
$117.12
▼-1.85%
META
$742.91
▲+2.04%
NVDA
$238.60
▲+1.99%
SPCX
$167.42
▲+5.32%
MU
$1,062.81
▼-1.12%
TSLA
$380.21
▲+2.60%
MSFT
$525.79
▲+1.60%
SNDK
$1,705.07
▼-0.87%
INTC
$117.12
▼-1.85%
META
$742.91
▲+2.04%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Novartis AG Common Stock
(NY:
NVS
)
140.36
-0.64 (-0.46%)
Delayed Quote
Updated: 2:38 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
59
60
Next >
Non-Small Cell Lung Cancer Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, AstraZeneca, Bristol-Myers, Roche
June 21, 2023
Via
AB Newswire
Neuroblastoma Market to witness growth by 2032, estimates DelveInsight | Aptorum, Athenex, Eli Lilly, Clarity Pharmaceuticals, Y-mAbs Therapeutics Inc, Novartis AG, Bristol-Myers Squibb, Roche
June 21, 2023
Via
AB Newswire
Pancreatic Cancer Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | ERYtech, FibroGen, Novartis, Eleison, Panbela, Redx Pharma, Immodulon, GSK, Merck
June 21, 2023
Via
AB Newswire
Nasal Polyposis Pipeline, Clinical Trials, NDA Approvals, and Emerging Drugs (2023) | Companies – AstraZeneca, Allakos, Idorsia Pharmaceuticals, Novartis, Regeneron Pharma, Sanofi, Amgen and others
June 21, 2023
Via
AB Newswire
Nasopharyngeal Cancer Pipeline, NDA Approvals, Clinical Trials, and Emerging Drugs (2023) | Companies – Novartis, Innovent Biologics, BeiGene, Merck, Tessa Therapeutics, and Others
June 21, 2023
Via
AB Newswire
Why Shares of Vera Therapeutics Jumped Tuesday
↗
June 20, 2023
The company announced early phase 2 trials information regarding its lead therapy.
Via
The Motley Fool
Vernal Keratoconjunctivitis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Santen, Novartis, Senju Pharma, Allakos, Astellas, Akari Therapeutics
June 20, 2023
Via
AB Newswire
Type 1 Diabetes Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest Drug Approvals, Clinical Trials, and Treatment Outlook | Novartis, Histogen, Vertex Pharma
June 20, 2023
Via
AB Newswire
Dry Eye Disease Market Size and Trends Analysis, Growth Opportunities, Clinical Trials Assessment, Emerging Therapies, Leading Companies, and Epidemiology Forecast | Novaliq, Alcon, Novartis, Novaliq
June 20, 2023
Via
AB Newswire
Blepharitis Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Allergan Plc, Bausch Health , Novartis, Pfizer, AxeroVision
June 20, 2023
Via
AB Newswire
Exploring the Neurofibromatosis Type 1 Pipeline: Advancing Towards a Latest Breakthroughs | Companies – NFlection, SpringWorks, Shanghai Fosun, Chia Tai Tianqing Pharma, Novartis, Array BioPharma
June 20, 2023
Via
AB Newswire
Innovations in Necrobiosis Lipoidica Pipeline Insights Report (2023): Companies – Novartis, Processa Pharmaceuticals, and Others
June 20, 2023
Via
AB Newswire
Metastatic Hormone Refractory Prostate Cancer Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies|Companies – Novartis, Astrazeneca, Merck, Clovis Oncology Inc Arcus Bioscience
June 19, 2023
Via
AB Newswire
Metastatic Hepatocellular Carcinoma Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies |Companies – Astrazeneca, Roche, Novartis, Chugai Pharmaceuticals, BeiGene
June 19, 2023
Via
AB Newswire
Biologics and Biosimilars Market Is Touching New Level – A Comprehensive Study with Key Players Amgen, AbbVie, Sanofi-Aventis
June 19, 2023
Biologics and Biosimilar Market Size, Status and Forecast 2028
Via
SBWire
Topics
Intellectual Property
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
↗
June 19, 2023
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union.
Via
The Motley Fool
Rett Syndrome Market to Observe Stupendous Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Neurolixis, Vyant Bio, Prilenia, StrideBio, Novartis, Ultragenyx
June 19, 2023
Via
AB Newswire
Complicated Urinary Tract Infection (cUTI) Market to Witness Growth by 2032, Estimates DelveInsight| Meiji Seika Pharma, Pfizer, Novartis, Spero Therapeutics, Tetraphase Pharmaceuticals, Wockhardt
June 16, 2023
Via
AB Newswire
Alcoholic Hepatitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Durect Corporation, Novartis, Intercept Pharma, Gilead Sciences
June 16, 2023
Via
AB Newswire
Beta Thalassemia Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Novartis, Hoffmann-La Roche, Vertex Pharma, Bristol-Myers Squibb, Sanofi, HemaQues
June 16, 2023
Via
AB Newswire
Neurofibromatosis Type-2 Pipeline, Clinical Trials, and Emerging Drugs (2023) | Companies – AstraZeneca, Recursion Pharma, Betta Pharma, Novartis Pharma, Genentech, Takeda, and others
June 16, 2023
Via
AB Newswire
Netherton Syndrome Pipeline, NDA Approvals, Emerging Drugs and Clinical Trials (2023) | Companies – Novartis, Timber Pharma, Bridge Biopharma, Evotec AG, Dermelix Biotherapeutics, Krystal Biotech.
June 16, 2023
Via
AB Newswire
Coherus BioSciences Acquires Small Immuno-Oncology Player Surface Oncology For $40M
↗
June 16, 2023
Coherus BioSciences Inc (NASDAQ: CHRS) has agreed to acquire Surface Oncology Inc (NASDAQ: SURF), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that
Via
Benzinga
Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review
↗
June 16, 2023
Stocks kept powering higher despite, but the Nasdaq is looking extended.
Via
Investor's Business Daily
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
↗
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
Cryopyrin Associated Periodic Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 |Companies – Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics
June 15, 2023
Via
AB Newswire
Craniopharyngioma Pipeline, Clinical Trials, and Key Companies|Companies – Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen
June 15, 2023
Via
AB Newswire
Paroxysmal Nocturnal Hemoglobinuria Market and Epidemiology 2032 by DelveInsight | Roche, Alexion Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceutical
June 15, 2023
Via
AB Newswire
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
↗
June 14, 2023
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a
Via
Benzinga
Ocular Melanoma Market expected to rise | Companies – Eli Lilly & Co, Spectrum Pharmaceuticals Inc, Novartis AG, Bayer, AstraZeneca plc, Merck, Amgen, Pfizer Inc, Roche, expected to drive market
June 14, 2023
Via
AB Newswire
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
59
60
Next >
